Logo Logo
Switch Language to German

Rüssel, J.; Einem, J. von; Keilholz, U.; Dietz, A.; Grünewald, V; Maschmeyer, G.; Kasper, S.; Rupprecht, M.; Sasse, B.; Melillo, G. and Krauss, J. (2016): RAPTOR, the global phase II, III clinical development program of the PD-L1 inhibitor Durvalumab (MEDI4736) in 2nd-line recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) - A German update on the HAWK, EAGLE and CONDOR trials. In: Oncology Research and Treatment, Vol. 39: pp. 173-174

Full text not available from 'Open Access LMU'.

Actions (login required)

View Item View Item